Biogen ALS Drug Showed No Benefit, O'Neill Says

Jan. 3 (Bloomberg) -- Gilmore O’Neill, vice president of clinical development at Biogen Idec Inc., talks with Bloomberg's Meg Tirrell about the company's announcement that its experimental drug for amyotrophic lateral sclerosis failed to help patients in a clinical trial. Biogen sank 1.4 percent to $147.86 at 4 p.m. New York time after saying it will end development of the medicine for ALS, also known as Lou Gehrig’s disease. (Source: Bloomberg)
JPMorgan’s Juvyns Says Fed Has Backed Itself in a Corner
29:41 - JPMorgan Global Market Strategist Vincent Juvyns discusses timing for a Federal Reserve rate and its impact on Europe. He speaks with Jonathan Ferro on Bloomberg Television’s “On The Move.” (Source: Bloomberg)
  • Outlook for Global Growth: Are We in Deep Trouble?
  • Rate Cut: Will the RBI Spring Into Action?
  • Paris's Thriving Startup Scene